Literature DB >> 26878793

Resveratrol is equipotent to perindopril in attenuating post-infarct cardiac remodeling and contractile dysfunction in rats.

Pema Raj1, Basma Milad Aloud1, Xavier Lieben Louis1, Liping Yu2, Shelley Zieroth3, Thomas Netticadan4.   

Abstract

BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors improve prognosis in patients with post-myocardial infarction (MI) related cardiac dysfunction. Resveratrol is a polyphenol that has been reported to be beneficial in hypertension, ischemic heart disease, and cardiotoxicity in preclinical studies. Accordingly, we investigated the comparative and combinatorial efficacy of resveratrol and perindopril (ACE inhibitor) treatment on MI-related cardiac remodeling and contractile dysfunction.
METHODS: Left anterior descending artery-ligated and sham-operated male Sprague-Dawley rats were gavaged with vehicle, resveratrol, perindopril, and combination of resveratrol+perindopril (2.5 mg/kg bodyweight/day) for 8 weeks (starting immediately after acute MI). Echocardiography was performed to assess cardiac structure and function at baseline and 8 weeks.
RESULTS: At 8 weeks, vehicle-MI rats had a significantly lower left ventricular ejection fraction (LVEF) and increased LV dilatation compared to vehicle-sham rats. MI rats treated with resveratrol, perindopril and a combination of both had significantly improved LVEF and reduced LV dilatation. Vehicle-treated MI rats also had increased level of lipid peroxidation product- malondialdehyde (MDA), proinflammatory protein- tumor necrosis factor-alpha (TNF-α) and cardiac fibrosis marker- collagen and decreased enzymatic activity of superoxide dismutase and catalase compared to vehicle-sham rats. Resveratrol, perindopril and combination of both significantly prevented the /ed to determine systolic functional parameter increase in MDA, TNF-α and collagen and improved the activity of superoxide dismutase and catalase in MI rats compared to vehicle-MI rats.
CONCLUSION: Treatment with resveratrol or perindopril was equivalent in significantly improving remodeling and attenuation of contractile dysfunction in MI rats. Combination treatment also attenuated the cardiac abnormalities. The improvement in cardiac abnormalities may partly be through reducing oxidative stress by preventing the decrease in the activity of superoxide dismutase and catalase, and decreasing cardiac inflammation and fibrosis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute myocardial infarction; Cardiac dysfunction; Cardiac remodeling; Perindopril; Resveratrol

Mesh:

Substances:

Year:  2015        PMID: 26878793     DOI: 10.1016/j.jnutbio.2015.09.025

Source DB:  PubMed          Journal:  J Nutr Biochem        ISSN: 0955-2863            Impact factor:   6.048


  7 in total

Review 1.  RAS inhibition in resident fibroblast biology.

Authors:  Alexandra M Garvin; Bilal S Khokhar; Michael P Czubryt; Taben M Hale
Journal:  Cell Signal       Date:  2020-12-25       Impact factor: 4.315

2.  Transgenic overexpression of GTP cyclohydrolase 1 in cardiomyocytes ameliorates post-infarction cardiac remodeling.

Authors:  Yanan Liu; Shelley L Baumgardt; Juan Fang; Yang Shi; Shigang Qiao; Zeljko J Bosnjak; Jeannette Vásquez-Vivar; Zhengyuan Xia; David C Warltier; Judy R Kersten; Zhi-Dong Ge
Journal:  Sci Rep       Date:  2017-06-08       Impact factor: 4.379

3.  Evaluation of Oxidative Stress in Cardiomyocytes during the Aging Process in Rats Treated with Resveratrol.

Authors:  P Aguilar-Alonso; O Vera-López; E Brambila-Colombres; O Segura-Badilla; R Avalos-López; M Lazcano-Hernández; A R Navarro-Cruz
Journal:  Oxid Med Cell Longev       Date:  2018-05-02       Impact factor: 6.543

Review 4.  A Comprehensive Analysis of the Efficacy of Resveratrol in Atherosclerotic Cardiovascular Disease, Myocardial Infarction and Heart Failure.

Authors:  Pema Raj; Sijo Joseph Thandapilly; Jeffrey Wigle; Shelley Zieroth; Thomas Netticadan
Journal:  Molecules       Date:  2021-10-31       Impact factor: 4.411

Review 5.  Role of resveratrol in inhibiting pathological cardiac remodeling.

Authors:  Shaowei Fan; Yuanhui Hu; Yaping You; Wenjing Xue; Ruoning Chai; Xuesong Zhang; Xintian Shou; Jingjing Shi
Journal:  Front Pharmacol       Date:  2022-09-01       Impact factor: 5.988

6.  Resveratrol improves cardiac function and left ventricular fibrosis after myocardial infarction in rats by inhibiting NLRP3 inflammasome activity and the TGF-β1/SMAD2 signaling pathway.

Authors:  Jinjin Jiang; Xiuping Gu; Huifeng Wang; Shibin Ding
Journal:  PeerJ       Date:  2021-05-28       Impact factor: 2.984

7.  LuQi Formula Regulates NLRP3 Inflammasome to Relieve Myocardial-Infarction-Induced Cardiac Remodeling in Mice.

Authors:  Xiaoqing Zhang; Dandan Zhao; Jiling Feng; Xiaoli Yang; Zhenzhen Lan; Tao Yang; Xiaoni Kong; Huiyan Qu; Hua Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-28       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.